Difference between revisions of "Periampullary adenocarcinoma"
Jump to navigation
Jump to search
m (→Placebo) |
|||
| Line 29: | Line 29: | ||
=Adjuvant therapy= | =Adjuvant therapy= | ||
| − | == | + | ==Observation== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
| − | |||
===Regimen=== | ===Regimen=== | ||
{| class="wikitable" style="width: 100%; text-align:center;" | {| class="wikitable" style="width: 100%; text-align:center;" | ||
| Line 41: | Line 40: | ||
!style="width: 25%"|Comparator | !style="width: 25%"|Comparator | ||
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | ||
| + | |- | ||
| + | |[https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.10831 Takada et al. 2002] | ||
| + | |style="background-color:#1a9851"|Phase III (C) | ||
| + | |5-FU & Mitomycin | ||
| + | |style="background-color:#ffffbf"|Seems not superior | ||
|- | |- | ||
|[http://jamanetwork.com/journals/jama/fullarticle/1216477 Neoptolemos et al. 2012 (ESPAC-3)] | |[http://jamanetwork.com/journals/jama/fullarticle/1216477 Neoptolemos et al. 2012 (ESPAC-3)] | ||
| Line 48: | Line 52: | ||
|- | |- | ||
|} | |} | ||
| + | ''No adjuvant therapy.'' | ||
====Preceding treatment==== | ====Preceding treatment==== | ||
*Surgery | *Surgery | ||
===References=== | ===References=== | ||
| + | # Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T; Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002 Oct 15;95(8):1685-95. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.10831 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12365016 PubMed] | ||
# '''ESPAC-3:''' Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW; European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012 Jul 11;308(2):147-56. Erratum in: JAMA. 2012 Nov 14;308(18):1861. [http://jamanetwork.com/journals/jama/fullarticle/1216477 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22782416 PubMed] | # '''ESPAC-3:''' Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW; European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012 Jul 11;308(2):147-56. Erratum in: JAMA. 2012 Nov 14;308(18):1861. [http://jamanetwork.com/journals/jama/fullarticle/1216477 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22782416 PubMed] | ||
Revision as of 22:15, 10 November 2018
| Section editor | Page editor | ||
|---|---|---|---|
 |
Neeta K. Venepalli, MD, MBA Chicago, IL |
 |
Ivy Abraham, MD Chicago, IL |
0 regimens on this page
0 variants on this page
|
Liver cancer or hepatobiliary cancer comprises cancers that arise within the liver and its hepatocytes (hepatocellular carcinoma) and the biliary tract cancers, which include bile duct cancer/cholangiocarcinoma and gallbladder cancer.
Guidelines
ESMO
- 2016: Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. PubMed
NCCN
Adjuvant therapy
Observation
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Takada et al. 2002 | Phase III (C) | 5-FU & Mitomycin | Seems not superior |
| Neoptolemos et al. 2012 (ESPAC-3) | Phase III (C) | 1. 5-FU & Leucovorin 2. Gemcitabine |
Seems not superior |
No adjuvant therapy.
Preceding treatment
- Surgery
References
- Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T; Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002 Oct 15;95(8):1685-95. link to original article PubMed
- ESPAC-3: Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW; European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012 Jul 11;308(2):147-56. Erratum in: JAMA. 2012 Nov 14;308(18):1861. link to original article PubMed